Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2017-05-19 Director's Dealing
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2017-05-19 English
PRIMARY DOCUMENT
Director's Dealing
2017-05-19 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3ASR registration statement filed with the SEC, which is a shelf registration statement used by companies to register securities for sale to the public. It includes a prospectus describing the terms of potential common stock offerings and references to supplements and amendments for specific offerings. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or notice. Hence, the classification is CAP with high confidence.
2017-05-19 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 15, 2017, for Insmed Incorporated. The content focuses on the appointment of new officers: a Chief Financial Officer and a Chief Medical Officer, as well as a transition of an existing officer to a new role. It details their backgrounds, compensation, and employment agreements. There is no financial data, earnings information, or report publication mentioned. The primary subject is changes in senior management positions. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document is not a full report, earnings release, or regulatory filing of another type. Therefore, the correct classification is MANG with high confidence.
2017-05-19 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 3, 2017, by Insmed Incorporated. It specifically references Item 2.02 - Results of Operations and Financial Condition, indicating that the company issued a press release regarding its financial results for the quarter ended March 31, 2017. The document states that the press release is furnished as an exhibit and is not filed for purposes of Section 18 of the Exchange Act. The length of the document is 3563 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing detailed financial statements or analysis. Therefore, this document is best classified as an Earnings Release (ER) since it announces quarterly financial results highlights via a press release.
2017-05-03 English
10-Q
Interim / Quarterly Report Q1 2017
2017-05-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.